Condition
Anal Cancer|Colorectal Cancer|Gallbladder Cancer|Gastric Cancer|Pancreatic Cancer
Estimated Enrollment: 29
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: ID97-027|P30CA016672|MDA-ID-97027|NCI-T97-0034|CDR0000065681
Study First Received: November 1, 1999
Last Updated: July 27, 2012
Estimated Primary Completion Date: October 2001
Primary Outcome Measures:
Maximum Tolerated Dose (MTD) of Intraperitoneal Interleukin-12
Sponsors and Collaborators:
M.D. Anderson Cancer Center|National Cancer Institute (NCI)
Website Link: https://ClinicalTrials.gov/show/NCT00003046
